Mohammadamin Noorafrooz, Robert Peter Gale, Mohadese Dashtkoohi
{"title":"Beyond CAR-T: The Rise of CAR-NK/T Cells for Haematological Cancer.","authors":"Mohammadamin Noorafrooz, Robert Peter Gale, Mohadese Dashtkoohi","doi":"10.1159/000547531","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chimeric antigen receptor (CAR)-natural killer (NK)/T-cells offer a new approach in immune therapy of haematological cancers. NK/T-cells bridge innate and adaptive immunity with strong anti-cancer effects. Unlike allogeneic CAR-T-cells, CAR-NK/T-cells do not require TCR genetic deletion to prevent major MHC recognition, have a lower risk of graft-versus-host disease, and can be used universally.</p><p><strong>Summary: </strong>Pre-clinical studies report CAR-NK/T-cells effectively target antigens such as CD19 and B-cell maturation antigen in B-cell lymphomas and plasma cell myeloma. Compared with CAR-T-cells, CAR-NK/T-cells have faster immune responses, more cytotoxicity and better safety. Recent innovations increase efficacy of CAR-NK/T-cell therapies. Early clinical trials report promising safety and efficacy. Although still in the early phases of development, advances in NK/T-cell therapy are overcoming prior challenges.</p><p><strong>Key messages: </strong>CAR-NK/T-cells may prove a safer, more flexible form of cell therapy of haematological cancers.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-15"},"PeriodicalIF":1.1000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547531","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Chimeric antigen receptor (CAR)-natural killer (NK)/T-cells offer a new approach in immune therapy of haematological cancers. NK/T-cells bridge innate and adaptive immunity with strong anti-cancer effects. Unlike allogeneic CAR-T-cells, CAR-NK/T-cells do not require TCR genetic deletion to prevent major MHC recognition, have a lower risk of graft-versus-host disease, and can be used universally.
Summary: Pre-clinical studies report CAR-NK/T-cells effectively target antigens such as CD19 and B-cell maturation antigen in B-cell lymphomas and plasma cell myeloma. Compared with CAR-T-cells, CAR-NK/T-cells have faster immune responses, more cytotoxicity and better safety. Recent innovations increase efficacy of CAR-NK/T-cell therapies. Early clinical trials report promising safety and efficacy. Although still in the early phases of development, advances in NK/T-cell therapy are overcoming prior challenges.
Key messages: CAR-NK/T-cells may prove a safer, more flexible form of cell therapy of haematological cancers.
期刊介绍：
''Acta Haematologica'' is a well-established and internationally recognized clinically-oriented journal featuring balanced, wide-ranging coverage of current hematology research. A wealth of information on such problems as anemia, leukemia, lymphoma, multiple myeloma, hereditary disorders, blood coagulation, growth factors, hematopoiesis and differentiation is contained in first-rate basic and clinical papers some of which are accompanied by editorial comments by eminent experts. These are supplemented by short state-of-the-art communications, reviews and correspondence as well as occasional special issues devoted to ‘hot topics’ in hematology. These will keep the practicing hematologist well informed of the new developments in the field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
